Treating sepsis associated acute kidney injury (AKI) with proprietary recombinant alkaline phosphatase (recAP). Results from Ph 2 trial in 300+ pts, demonstrated relative improvement of 40%+ OS in recAP group. Initiating Ph 3 in Q3 2020 – interim look (n=400) exp Q3 2021 (P endpoint: Day 28 all-cause mortality).
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Fall Private Company Showcase 2020
October 15, 2020